Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Bocidelpar
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
{{NeedsImage}} '''Bocidelpar''' or '''ASP0367''' or '''MA-0211''' is an experimental drug that may improve [[mitochondria]] and [[endothelial dysfunction|endothelial function]].<ref name="ppmd">{{Cite web | url = https://www.parentprojectmd.org/drug-development-pipeline/ma-0211-mtb-1/ | title = ASP0367 (MA-0211) | last = Mitobridge (Astellas)| first = | author-link = | date = | website = Parent Project Muscular Dystrophy|language=en-US|archive-url=|archive-date=|url-status= | access-date = 2022-04-25}}</ref> Bocidelpar is undergoing clinical trials under the name ASP0367 for Duchenne Muscular Dystrophy, [[ME/CFS]], [[hypoxia]], kidney failure and mitochondrial myopathies (which result in [[mitochondria dysfunction]]).<ref name="ppmd" /><ref name="NCT04855201">{{Cite web | title = A Phase 1b Multiple Oral Dose Study to Evaluate the Pharmacological Effect, Safety and Tolerability of ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction | date = 2022-04-14 | url = https://clinicaltrials.gov/ct2/show/NCT04855201 | last = Astellas Pharma Global Development, Inc.}}</ref><ref name="FastTrack">{{Cite web | title = U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator Being Developed for the Treatment of Primary Mitochondrial Myopathies | url = https://www.astellas.com/system/files/news/2020-10/20201020_en_1_2.pdf | website=Astrella Pharma|access-date=Apr 25, 2022}}</ref> Bocidelpar was developed by Astrella Pharma's subsidiary Mitobridge and is being fast tracked by the FDA.<ref name="ppmd" /><ref name="FastTrack"/> ==Theory== Bocidelpar is investigated to determine whether it can turn on the Peroxisome Proliferator-Activated Receptor delta (PPAR-δ) pathway, which is the pathway that turns on different genes in order to regulate mitochondria.<ref name="ppmd" /> The theory is that turning on this pathway will improve muscle function at a cellular level.<ref name="DMDpipeline">{{Cite web | url = https://www.parentprojectmd.org/duchenne-drug-development-pipeline/ | title = Duchenne Drug Development Pipeline | website = Parent Project Muscular Dystrophy|language=en-US | access-date = 2022-04-25}}</ref> ==Evidence== The first clinical trial for ME/CFS is trial NCT04855201, which has not yet published any results. The trial involves 40 adults aged between 18 and 60, and is randomized clinical trial with quadruple blinding.<ref name="NCT04855201" /> Clinicial trial results will look at oxygen uptake changes, exercise test values for [[aerobic exercise]] including measuring change in aerobic capacity and anaerobic threshold changes, with [[cardiopulmonary exercise testing]] being one of the tests carried out.<ref name="NCT04855201" /> ==Clinicians== [[David Systrom]] is helping conduct the current clinical trial of bocidelpar at Brigham and Women's Hospital, Boston, United States.<ref name="HR23Apr2022">{{Cite web | url = https://www.healthrising.org/blog/2022/04/23/mitochondrial-chronic-fatigue-syndrome/ | title = $8 Million Clinical Trial of a Mitochondrial Booster Underway in ME/CFS | last = Johnson | first = Cort | date = 2022-04-23 | website = Health Rising|language=en-US | access-date = 2022-04-25}}</ref> ==Risks and safety== Unknown. ==Costs and availability== ==See also== *[[Endothelial dysfunction]] *[[Palmitoylethanolamide]] (PEA) ==Learn more== *[https://www.parentprojectmd.org/drug-development-pipeline/ma-0211-mtb-1/ ASP0367 (MA-0211) development pipeline] *[https://clinicaltrials.gov/ct2/show/NCT04855201?term=ASP0367&draw=2&rank=5 A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction] - Clinical trial *April 2022, [https://www.healthrising.org/blog/2022/04/23/mitochondrial-chronic-fatigue-syndrome/ $8 Million Clinical Trial of a Mitochondrial Booster Underway in ME/CFS] - Cort Johnson, Health Rising *[https://www.mitobridge.com/about/science/ Science - Mitobridge] ==References== {{reflist}} [[Category:Potential treatments]] [[Category:PPAR modulators]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Cite web
(
edit
)
Template:Main other
(
edit
)
Template:NeedsImage
(
edit
)
Template:Reflist
(
edit
)
Module:Check for unknown parameters
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
This page is a member of a hidden category:
Category:Articles that need an image or photo
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs